23–24 July 2020
Patrick A. Brown, MD
Johns Hopkins University School of Medicine
Dr Patrick Brown is associate professor of oncology and pediatrics and director of the Pediatric Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine in Baltimore, MD.
Dr Brown earned a bachelor’s degree in engineering from the United States Military Academy in West Point, NY, and a master’s degree in philosophy and politics from Oxford University in England. After earning his medical degree from the Medical University of South Carolina in Charleston, Dr Brown was an intern and resident in pediatrics at Johns Hopkins, and subsequently completed a joint clinical fellowship with Johns Hopkins and the National Cancer Institute in pediatric hematology/oncology.
Dr Brown is the vice chair for relapse and an executive steering committee member of the ALL Committee in the Children’s Oncology Group, and chairs the National Comprehensive Cancer Network’s Clinical Guidelines Panels for adult and pediatric ALL. His research focuses on developing molecularly targeted therapies for high-risk childhood leukemias.
Roberta Demichelis, MD
Instituto Nacional de Ciencias Médicas y Nutrición Salvador, Zubirán, Mexico
Roberta Demichelis, MD, is an assistant professor in the Department of Hematology/Oncology at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ) in Mexico City, Mexico. She graduated from the Universidad Anáhuac School of Medicine in Mexico. She completed his residency in internal medicine and fellowship in hematology at the INCMNSZ. She later joined the faculty of the same institution, where she currently serves as the acute leukemia service coordinator.
Dr Demichelis is involved in clinical research with a focus on acute leukemia. She is coordinator of the Acute Leukemia Working Group of the Mexican Society of Hematology (Agrupación Mexicana para el Estudio de la Hematología). The group is carrying out different prospective multicentric studies focused on characterizing patients with acute leukemia and improving outcomes in the region. She actively participates in international American Society of Hematology initiatives, and was invited to be part of the Clinical Research Training Institute in Latin America faculty group.
Lia Gore, MD
University of Colorado, Anschutz, Medical Campus, USA
Dr Lia Gore is a professor with tenure at the University of Colorado School of Medicine, and chief of pediatric hematology/oncology/bone marrow transplant-cellular therapeutics at Children’s Hospital Colorado and the University of Colorado School of Medicine. She received her MD from George Washington University School of Medicine and Health Sciences in Washington, DC. She completed her internship in pediatrics at Children’s National Medical Center, and her pediatrics residency training and pediatric hematology/oncology fellowship and further postdoctoral training at the University of Colorado and Children’s Hospital Colorado.
Dr Gore’s research interests are focused on the development of novel cancer therapeutics, with an emphasis on pediatric and hematologic malignancies and improving access to clinical trials for children and adolescents. Her focus is on particularly high-risk diseases such as relapsed leukemia, sarcoma, and central nervous system tumors. She has been a principal investigator (PI) or co-investigator on more than 250 national and international clinical trials, including as the PI for trials leading to the approval of 4 drugs for childhood cancer.
Dr Gore serves on advisory panels of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration, the Developmental Therapeutics and Department of Defense Study Sections of the National Institutes of Health, and has advised the European Medicines Agency on pediatric investigational plans for oncology products. She has directed a research study portfolio of over $30 million dollars. She is a founding co-director of the University of Colorado National Cancer Institute-designated Comprehensive Cancer Center’s hematologic malignancies program. Dr Gore currently serves as a co-director of the developmental therapeutics program, and on the executive committee for acute lymphoblastic leukemia. She is the newly elected groupwide vice chair for the Children’s Oncology Group.
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center
Elias Jabbour, MD, is professor of medicine, Department of Leukemia, at The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX. He graduated from the Saint Joseph University School of Medicine, Beirut, and joined the Hotel Dieu de France University Hospital as a resident. He pursued a fellowship in hematology-oncology at the Gustave Roussy Institute, France. In 2003, he joined MDACC as a fellow in the Department of Hematology/Leukemia and Stem Cell Transplantation. He later joined the faculty in the Leukemia Department as assistant professor.
Dr Jabbour is actively involved in research both in acute and chronic forms of leukemia. He is currently investigating an innovative strategy combining new monoclonal antibodies such as inotuzumab ozogamicin, a conjugated anti-CD22 antibody, and blinatumomab with minimal chemotherapy. If successful, such strategies will likely increase the cure rates of adult patients with ALL to the high level achieved in pediatric patients.
Dr Jabbour has taken an active role in the medical community, participating in numerous scientific meetings. He has authored or co-authored numerous publications (>550 peer-reviewed publications) and abstracts, and serves as a reviewer for many scientific journals.
Franco Locatelli, MD
University of Rome, IRCCS Ospedale Pediatrico, Bambino Gesù, Italy
Prof Franco Locatelli is head of the Department of Paediatric Haematology and Oncology, IRCCS Bambino Gesù Children’s Hospital in Rome, and full professor of pediatrics at the Sapienza University of Rome in Italy. He leads the largest program of childhood allogeneic hematopoietic stem cell transplantation (HSCT) in Italy and was recently appointed president of the Italian Higher Council of Health (Consiglio Superiore di Sanità), the technical scientific advisory body to the Ministry of Health. He graduated in medicine and surgery from the University of Pavia in Italy, where he also obtained a specialization in pediatrics and hematology. In 2005, he received the Gold Medal for Merit in public health by the president of the Italian Republic.
Prof Locatelli is an expert in childhood hematologic and oncologic malignancies. He was the president of the Italian Association for Pediatric Hematology-Oncology from 2004 to 2006, and served as chairman of the EWOG-MDS consortium from 2005 to 2011. Currently, he coordinates the national protocols for children with newly diagnosed acute myeloid leukemia and relapsed acute lymphoblastic leukemia. He has implemented in Italy the first-in-human academic studies on children with CD19+ lymphoid malignancies using second-generation retroviral chimeric antigen receptor (CAR) T cells and on children with GD2+ neuroblastoma.
Prof Locatelli is also involved in the development and validation of gene therapy approaches in patients with thalassemia and sickle cell disease and he has extensive experience in running phase I/II clinical trials. He is the author or co-author of 1,070 peer-reviewed articles published in international journals and he has an overall impact factor above 5000 and an H-index of 99 (Scopus source).
Aaron Logan, MD, PhD
University of California, San Francisco, USA
Dr Aaron Logan is associate professor of clinical medicine, chair of the Hematologic Tissue Use Oversight Committee, and director of the Hematologic Malignancies Tissue Bank at the University of California, San Francisco (UCSF). He earned his medical degree, and PhD in molecular microbiology and immunology, from the Keck School of Medicine of the University of Southern California. He completed a residency in internal medicine, and fellowships in hematology and blood and marrow transplantation at Stanford University School of Medicine, CA.
Dr Logan specializes in the management of patients with hematologic malignancies, particularly those treatable by transplantation with allogeneic hematopoietic stem cells, including acute leukemias, myelodysplastic syndrome, chronic lymphocytic leukemia, aplastic anemia, and hemophagocytic lymphohistiocytosis. He also has expertise in the diagnosis, staging, and management of graft-vs-host disease. His research interests focus on the application of next-generation sequencing of immunoreceptor genes to quantify minimal residual disease in lymphoid malignancies, quantify B- and T-cell immune reconstitution after transplantation, and to quantify and track malignancy-, pathogen-, and autoantigen-targeted immune responses following transplantation or immunotherapy. In his role as director of the Hematologic Malignancies Tissue bank at UCSF, he collaborates with many investigators on elucidating the etiology of, and possible treatment for, various blood cancers, including leukemia, lymphoma, and myeloma.
Dr Logan is a member of the American Society of Hematology, American Society for Blood and Marrow Transplantation, and the National Comprehensive Cancer Network Electronic Health Record Advisory Group. His research has appeared in numerous peer-reviewed journals, including Clinical Cancer Research, Blood, Biology of Blood and Marrow Transplantation, and Journal of the National Comprehensive Cancer Network.
Eduardo M. Rego, MD, PhD
University of São Paulo, Brazil
Dr Eduardo Rego is full professor in the faculty of medicine at the Medical School of Ribeirão Preto, coordinator of the Acute Leukemia Service of the Cancer Institute of the State of São Paulo, and coordinator of hematology services of the D’Or Network, Brazil. He obtained his medical degree from the Medical School of Ribeirão Preto and his PhD in clinical medicine from the University of São Paulo. He was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center, New York, NY.
Dr Rego’s area of interest is hematologic neoplasias, with special emphasis on the study of pathophysiology and the development of new treatment strategies for acute leukemias.
He is a member of the steering committee and coordinator in Brazil of the International Consortium on Acute Leukemias (ICAL) of the American Society of Hematology (ASH). The clinical studies developed by ICAL in Latin America aim to improve the outcomes of treatments for acute leukemias in the region and promote the scientific advancement of hematology. Dr Rego is chair of the International Members Committee of ASH, and scientific vice-director of the Brazilian Association of Hematology, Hemotherapy and Cell Therapy. He is editor of the Brazilian Journal of Medical and Biological Research, deputy editor of Hematology, Transfusion and Cell Therapy, and associate editor of Annals of Hematology.